Nobiletin enhances Doxorubicin sensitivity in osteosarcoma through ER stress-induced apoptosis mediated by the PI3K/AKT pathway - PubMed
7 hours ago
- #apoptosis
- #chemotherapy-resistance
- #osteosarcoma
- Nobiletin (Nob) enhances Doxorubicin (Dox) sensitivity in osteosarcoma (OS) cells.
- Combined Nob and Dox treatment inhibits OS cell proliferation and migration synergistically.
- The combination increases apoptosis via reduced Bcl-2 and elevated Bax and Caspase3 expression.
- ERS-related proteins (GRP78, CRT, CHOP, ATF6) are upregulated with Nob and Dox treatment.
- PI3K-AKT pathway activity is significantly diminished by the combination therapy.
- In vivo, Nob and Dox combination inhibits tumor growth and induces ERS and apoptosis.
- Nob enhances Dox-induced ERS and apoptosis by inhibiting the PI3K-AKT pathway.